News

Additionally, the company has announced a change in its name from Reata Discovery, Inc to Reata Pharmaceuticals Inc to reflect the clinical status of its drug development programs.

Kadian is Alpharma’s branded sustained release morphine sulfate product and is currently marketed in 20mg, 30mg, 50mg, 60mg and 100mg dosages. The company plans to launch the new

The biotechnology company reviewed both this study and additional preclinical data conducted with outside collaborators, before concluding the drug was ready for further investigation. CTCE-9908 is designed to

Following notice given in December 2004 that the FDA would not approve the product for release after the company’s first submission, Cellegy has provided a written response containing

The research collaboration, which began in August 2002 aims to identify specific small molecule drug candidates against a ligase target that controls the spreading of cancer cells through

The multi-center study is designed to evaluate clinical safety of SB-509 in diabetics with mild to moderate diabetic peripheral sensory motor neuropathy in the legs. The trial, cleared

The trial is a double-blind, placebo- controlled, multinational clinical study using patients with advanced chronic heart failure. Vasogen has enrolled over 2,000 patients at 173 clinical sites in

In collaboration with Dr Scott Plevy, a clinical gastroenterologist at the University of Pittsburgh Medical Center, SP304 was shown to be effective in preliminary experiments conducted in an

The gene therapy company, in collaboration with the Institute of Ophthalmology in London, has presented data showing that two versions of the RetinoStat product are efficacious in an